James M. Daly

Director

Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. Over the course of his career, he has built market-leading global franchises across multiple therapeutic categories, with a particular focus in oncology. Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his time, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to Incyte, Daly was Senior Vice President of North America Commercial Operations, Global Marketing and Commercial Development for Amgen, with P&L responsibility for all U.S. and Canadian businesses. Daly also served as Vice President and General Manager for Amgen’s Oncology Business Unit. His teams at Amgen were responsible for numerous successful product launches, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Mr. Daly began his career in the pharmaceutical industry at GlaxoSmithKline where he held positions of increasing responsibility over a 16-year period, including Senior Vice President and General Manager of the company’s Respiratory and Anti-infective Business Unit, where he led the U.S. launch of Advair®, and also served as the Senior Vice President of U.S. Marketing. Mr. Daly serves on the board of directors of Acadia Pharmaceuticals, Inc., argenx SE, Bellicum Pharmaceuticals, Inc., and Madrigal Pharmaceuticals, Inc. He earned a Bachelor of Science degree in Pharmacy and Master of Business Administration from the State University of New York at Buffalo. Mr. Daly serves on the Nominating and Corporate Governance Committee and the Audit Committee.